Weiguang Yu

Weiguang Yu

Auto-generated profile, based on publicly available information

Weiguang Yu

Department of Orthopedics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SCSong Chen
Song Chen
BXBo Xu
Bo Xu
ZWZhiqiang Wu
Zhiqiang Wu
WPWang Pengfei
Wang Pengfei
WYWeiguang Yu
Weiguang Yu
WGWen Guo
Wen Guo
Background: Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrolizumab plus lenvatinib plus hepatic arterial infusion chemotherapy (HAIC) versus pembrolizumab plus lenvatinib in selected populations of patients with treatment-naive uHCC exhibiting programmed cell death ligand-1 (PD-L1) staining. Methods: Consecutive patients with treatment-naive uHCC exhibiting PD-L1 staining who were treated with pembrolizumab plus lenvatinib plus HAIC (PLH) or pembrolizumab plus lenvatinib (PL) were retrospectively identified from our medical centres from 2018 to 2021. HAIC involved oxaliplatin, fluorouracil, and leucovorin (FOLFOX). Follow-up occurred every 3 weeks for 1 year and then every 6 weeks thereafter. The primary endpoints included overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the frequency of key adverse events (AEs). Results: In total, 248 treatment-naive patients were retrospectively reviewed, 78 of whom were ineligible on the basis of the current criteria. Thus, 170 patients (PLH: n = 84, median age 52 years [range, 42–67]; PL: n = 86, 53 years [range, 43–69]) were eligible for the analysis. The median follow-up was 18.6 months (range, 1–26). At the final follow-up, the median OS was 17.7 months (95% confidence interval [CI], 15.2–18.3) in the PLH group versus 12.6 months (95% CI, 11.1–13.7) in the PL group (hazard ratio [HR] 0.52; 95% CI, 0.36–0.75; p = 0.001). A significant difference was also detected in the median PFS (10.9 months [95% CI, 8.7–11.4] for PLH vs. 6.8 months (95% CI, 5.2–7.4) for PL; HR 0.61, 95% CI, 0.43–0.85; p = 0.001). Significant differences in the rate of the key AEs were noted between groups (79.8% for PLH vs. 62.8% for PL, p = 0.015), but these AEs were controllable. Conclusions: Among selected populations of patients with treatment-naive uHCC exhibiting PD-L1 staining, the PLH regimen may substantially improve the survival benefits compared with the PL regimen with a controllable safety profile.

13 April 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HLHuanyi Lin
Huanyi Lin
QLQilong Liu
Qilong Liu
XZXianshang Zeng
Xianshang Zeng
WYWeiguang Yu
Weiguang Yu
GXGuixing Xu
Guixing Xu
Background: The purpose of this retrospective study was to evaluate the survival outcomes of pembrolizumab (PEM) plus enzalutamide (ENZ) versus PEM alone in selected populations of men with previously untreated metastatic castration-resistant prostate cancer (mCRPC) harbouring programmed cell death ligand-1 (PD-L1) staining.Methods: Consecutive men with previously untreated mCRPC harbouring PD-L1 staining who underwent treatment with PEM plus ENZ (PE) or PEM alone (PA) at our medical centre from January 1, 2017, to January 31, 2021, were retrospectively identified. Follow-up was conducted monthly during the first year and then every 1 month thereafter. The primary outcomes of the study were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were the frequency of key adverse events (AEs).Results: In total, 302 men were retrospectively reviewed, 96 of whom were deemed to be ineligible per the exclusion criteria, leaving 206 men (PE:n = 100, median age 64 years [range, 43–85] and PA:n = 106, 65 years [range, 45–82]) who were eligible for the study. The median follow-up for both groups was 34 months (range, 2–42). At the final follow-up, the median OS was 25.1 months (95% confidence interval [CI], 22.3–27.6) in the PE group versus 18.3 months (95% CI, 16.5–20.9) in the PA group (hazard ratio [HR] 0.56; 95% CI, 0.39–0.80;p = 0.001). A marked distinction was also observed in the median PFS (6.1 months [95% CI, 4.7–7.8] for PE vs. 4.9 months for PA (95% CI, 3.2–6.4) for PA; HR 0.55, 95% CI, 0.41–0.75;p = 0.001). There were noteworthy differences in the rate of the key AEs between the two groups (72.0% for PE vs. 45.3% for PA,p < 0.001). Noteworthy differences were also detected for fatigue events (7.0% in the PE group vs. 0.9% in the PA group,p = 0.025) and musculoskeletal events (9.0% for PE vs. 0.9% for PA,p = 0.007), but these events tended to be manageable.Conclusions: Among selected populations of men with previously untreated mCRPC harbouring PD-L1 staining, PEM added to ENZ treatment may significantly increase the survival benefits compared with PEM treatment alone regardless of tumor mutation status. The safety profile for PE plus ENZ tends to be manageable.

1 January 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
BXBo Xu
Bo Xu
HCHuihui Cheng
Huihui Cheng
KLKunhong Li
Kunhong Li
YLYukai Lv
Yukai Lv
XZXianshang Zeng
Xianshang Zeng
WGWenbo Guo
Wenbo Guo
Purpose: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. Methods: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). Results: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46–75]; CN: n = 64, 63 years [47–72]). The median duration of follow-up was 27 months [range 1–37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3–22.5) in the ACN group vs. 14.8 months (95% CI 12.5–17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33–0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7–9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6–6.8; HR 0.60; 95% CI 0.38–0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. Conclusion: Among selected populations of individuals with treatment-naïve, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile.

6 October 2022 in Geriatric Orthopaedic Surgery & Rehabilitation
Verified
Journal Article
Open access
THTao Huang
Tao Huang
SZShi Zhang
Shi Zhang
XLXinhang Liu
Xinhang Liu
GLGang Lv
Gang Lv
HHHeng Huang
Heng Huang
THTing Huang
Ting Huang
Introduction: The aim of this retrospective study was to assess the clinical outcomes of cemented or uncemented total hip arthroplasty (CTHA or UTHA) following prior failed proximal femoral nail antirotation (PFNA) fixation in patients with intertrochanteric femur fractures (IFFs). Materials and methods: Data from 244 patients with IFFs who experienced a conversion of PFNA to CTHA (n = 120) or to UTHA (n = 124) due to screw cut-out, mal/nonunion, or osteonecrosis during 2008-2018 were retrospectively analyzed. Follow-up occurred 1, 3, 6, and 12 months postoperatively and yearly thereafter. The primary outcome was the incidence of orthopedic complications; the secondary outcome was the Harris hip score (HHS). Results: The median follow-up was 60 months (range, 50-67 months). The incidences of orthopedic complications were 10% in the PFNA to CTHA group and 19.3% in the PFNA to UTHA group (P = .040). Significant differences were also observed regarding the incidence of prosthesis revision (1.7% for PFNA to CTHA vs 7.2% for PFNA to UTHA, P = .036). From the three years after conversion surgery to the final follow-up, significant differences were detected in HHS between groups (each P < .05). At the final follow-up, a statistically significant difference was detected in the HHS (79.54±18.85 for PFNA to CTHA vs. 75.26±18.27 for PFNA to UTHA, P = .014). Conclusion: The results of the study may demonstrate a significant statistical advantage with respect to the orthopedic complication rate and HHS in favor of CTHA compared to UTHA in patients with failed PFNA.

2 February 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YCYaolin Chen
Yaolin Chen
XLXiangzhen Liu
Xiangzhen Liu
JLJijun Liu
Jijun Liu
DLDonghua Liang
Donghua Liang
MZMingdong Zhao
Mingdong Zhao
PCPengfei Chen
Pengfei Chen
BackgroundCurrently, the choice of treatment for individuals with metastatic soft tissue sarcomas (MSTS) presents a significant challenge to clinicians. The aim of this retrospective study was to assess the efficacy and safety of nivolumab plus ipilimumab (NPI) versus nivolumab alone (NIV) in individuals with treatment-naive programmed death-ligand 1 (PD-L1) positive MSTS.MethodsProspectively maintained databases were reviewed from 2013 to 2018 to assess individuals with treatment-naive PD-L1 MSTS who received NPI (nivolumab 3mg/kg and ipilimumab 1mg/kg every 3weeks for 4 doses followed by nivolumab 3mg/kg every 2weeks) or NIV (3mg/kg every 2weeks) until disease progression, withdrawal, unendurable [AEs], or death. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS).ResultsThe median follow-up was 16.0months (IQR 14.4-18.5) after targeted intervention. The median OS was 12.2months (95% confidence interval [CI], 6.1-13.7) and 9.2months (95% CI, 4.2-11.5) for the NPI and NIV groups, respectively (hazard ratio [HR] 0.49, 95% CI, 0.33-0.73; p=0.0002); the median PFS was 4.1months (95% CI, 3.2-4.5) and 2.2months (95% CI, 1.1-3.4) for the NPI and NIV groups, respectively (HR 0.51, 95% CI, 0.36-0.71; p<0.0001). Key grade 3-5 AEs occurred more frequently in the NPI group than in the NIV group (94 [72.9%] for NPI vs. 35 [27.1%], p<0.001).ConclusionsFor treatment-naive PD-L1 positive MSTS, NPI seems to be less tolerated but has a greater survival advantage than NIV as the primary therapy.

29 April 2025 in Frontiers in Dental Medicine
Verified
Journal Article
Open access
PDF file
YCYanfei Cheng
Yanfei Cheng
ZLZhifen Lai
Zhifen Lai
WYWeiguang Yu
Weiguang Yu
Objective: This retrospective cohort study aimed to compare survival rates between immediate (≤24 h post-extraction) and delayed (3–4 months post-extraction) dental implants and to identify patient- and site-specific risk factors for implant failure, with emphasis on anatomical site, sex, and osteoporosis.Methods: We analyzed 1,500 implants (300 immediate, 1,200 delayed) from patients treated at the Guangdong Provincial Hospital of Traditional Chinese Medicine (2005–2023). Kaplan–Meier analysis evaluated cumulative survival rates over 72 months, with Cox regression modeling to assess predictors of failure. Propensity score matching (PSM) addressed baseline covariate imbalances.Results: Delayed implants exhibited significantly higher survival rates than immediate implants at 72 months (81.1% vs. 53.2%, p < 0.0001). Survival divergence intensified after 24 months, with delayed implants retaining 979 patients at risk vs. 202 for immediate implants. Mandibular sites consistently outperformed maxillary sites in both strategies (delayed: 88.5% vs. 72.2%; immediate: 70.5% vs. 40.7%, p < 0.0001). Male sex (HR: 1.64, 95% CI: 1.28–1.88; p < 0.001) and osteoporosis (HR: 2.50, 95% CI: 1.17–4.52; p = 0.024) emerged as independent risk factors, while tobacco use, diabetes, and hypertension showed no significant associations. PSM resolved most baseline imbalances, with post-matching standardized mean differences (SMD) <0.1 for key covariates.Conclusions: Delayed implantation at 3–4 months post-extraction provides superior intermediate-term survival, particularly in mandibular sites. Male patients and individuals with osteoporosis face elevated failure risks, warranting tailored clinical protocols. While both strategies remain viable, delayed placement is recommended for high-risk populations to optimize long-term outcomes.